© Copyright Acquisition International 2024 - All Rights Reserved.

Article Image - McDermott Will & Emery Advises Biota’s Acquisition of Anaconda Pharma
Posted 6th August 2015

McDermott Will & Emery Advises Biota’s Acquisition of Anaconda Pharma

McDermott Will & Emery Advises Biota's Acquisition of Anaconda Pharma

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

McDermott Will & Emery Advises Biota’s Acquisition of Anaconda Pharma

McDermott Will & Emery Advises Biota’s Acquisition of Anaconda Pharma

View Biography
Image

International law firm McDermott Will & Emery advised the shareholders of Anaconda Pharma on the sale of the company to Biota Pharmaceuticals.

Anaconda Pharma was formed in 2003 as a spin-out of the Institut Pasteur and is focused on the development of treatments against human papillomavirus (HPV) infections.   Under the agreement, all of Anaconda Pharma’s shares will be acquired for shares of Biota common stock and $8 million in cash, subject to certain adjustments. Biota Pharmaceuticals, Inc. is a company focused on the discovery and development of products to treat serious viral respiratory infectious diseases.

Biota will fund the cash portion of the purchase price with cash on hand. Anaconda’s shareholders may earn up to $30 million if the company achieves certain clinical and regulatory milestones, in addition to a royalty.  The deal is expected to occur by the end of April 2015, subject to approval of the French Ministry of Finance and Economics and other customary conditions.

Anaconda Pharma’s lead candidate is AP611074, a patented, direct-acting antiviral in development for the treatment of condyloma, or anogenital warts, as well as the orphan disease recurrent respiratory papillomatosis, both of which are caused by HPV types 6 and 11. Anaconda Pharma successfully completed a Phase 2a clinical trial of AP611074 5% gel demonstrating biological activity with a significant reduction in the surface area of condyloma while exhibiting favorable local skin tolerability.

Reflecting McDermott’s life science capabilities and global platform, Anaconda Pharma’s shareholders were represented by attorneys in McDermott’s Paris, New York and Washington DC offices, including Emmanuelle Trombe, Anthony Paronneau, Noëmie Fort, Antoine Vergnat, Christophe Jolk, Jilali Maazouz and Myrtille Lapuelle, Joel L. Rubinstein and Elliott Smith.

Categories: Legal, M&A


You Might Also Like
Read Full PostRead - Eye Icon
CVS to buy Omnicare for $12.7 Billion
M&A
22/05/2015CVS to buy Omnicare for $12.7 Billion

Deal to boost pharmacy chain’s services for the growing elderly population.

Read Full PostRead - Eye Icon
Success in the Mining Market
Leadership
29/07/2020Success in the Mining Market

Making a name for yourself in the world of business is no mean feat, especially if you’re a woman. With institutional biases and societal norms stacked against them, achieving success is something to be celebrated. Anna Stylianides is one of these names, ear

Read Full PostRead - Eye Icon
The Role of Technology in Modern Business Operations
Innovation
27/03/2023The Role of Technology in Modern Business Operations

In today's fast-paced and highly competitive business landscape, technology has become an indispensable tool that is used to optimize and streamline business operations.

Read Full PostRead - Eye Icon
Italian Firm Finds International Success
Legal
22/03/2020Italian Firm Finds International Success

The intricacies of law can lead some companies to become specialists in their specific geographic areas, but it can also inspire businesses to look further afield for ways in which to operate and innovate. One of the firms that sees innovation as essential is

Read Full PostRead - Eye Icon
What to Do After a Workplace Injury
Legal
22/04/2022What to Do After a Workplace Injury

Following an injury at your workplace, you have the right to workers' compensation benefits to cater for your medical bill, lost wages, and possible disability. Nevertheless, it's challenging to know what to do when you're ill or injured.

Read Full PostRead - Eye Icon
Where Next for Euro Government Bonds?
Finance
20/02/2015Where Next for Euro Government Bonds?

The ECB published its first-ever minutes of a policy meeting, revealing plans to expand its Quantitative Easing (QE) programme.

Read Full PostRead - Eye Icon
AIXTRON Acquires PlasmaSi
M&A
15/04/2015AIXTRON Acquires PlasmaSi

AIXTRON a leading provider of deposition equipment to the semiconductor industry, today announced that it has acquired privately held Silicon Valley-based PlasmaSi, Inc. effective April 1, 2015.

Read Full PostRead - Eye Icon
Merkle Acquires Leading US Digital Agency
M&A
04/11/2016Merkle Acquires Leading US Digital Agency

Merkle, a leading technology-enabled, data-driven performance marketing agency, announced its acquisition of Salt Lake City based Axis41, a leading strategic digital agency focused on customer experience.

Read Full PostRead - Eye Icon
The Impacts of Corporate Tax Reform III
Legal
04/01/2017The Impacts of Corporate Tax Reform III

We are a full-service business law firm. This enables us to render all our services as integrated services across legal areas. Most of our clients are multinational businesses. The firm was established 1911, so we have a history of 105 years now. This makes us



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow